SQZ Biotechnologies Company (SQZ) |
|
0.6041 -0.196 (-24.49%)
|
03-24 16:00 |
|
Open: |
0.742 |
Pre. Close: |
0.8 |
|
High:
|
0.7579 |
Low:
|
0.54 |
|
Volume:
|
1,960,942 |
Market Cap:
|
18(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:30:08 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 0.86  One year: 1.01 |
| Support: |
Support1: 0.52 Support2: 0.44 |
| Resistance: |
Resistance1: 0.74 Resistance2: 0.87 |
| Pivot: |
0.64 |
| Moving Average: |
MA(5): 0.63  MA(20): 0.67
MA(100): 1.23 MA(250): 2.44 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 48.4 %D(3): 37.4 |
| RSI: |
RSI(14): 44.4 |
| 52-week: |
High: 5.19 Low: 0.52 |
| Average Vol(K): |
3-Month: 330 (K) 10-Days: 1,350 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SQZ ] has closed above bottom band by 39.1%. Bollinger Bands are 34.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.76 - 0.76 |
0.76 - 0.76 |
|
Low:
|
0.53 - 0.54 |
0.54 - 0.54 |
|
Close:
|
0.6 - 0.6 |
0.6 - 0.61 |
|
Company Description |
|
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts. |
Headline News |
Thu, 23 Mar 2023
Health Care Sector Update for 03/23/2023: SQZ, ETNB, PRTC ... - Nasdaq
Thu, 23 Mar 2023
Sqz Biotechnologies Company Up 27.67% To $0.77 After Earnings Beat - InvestorsObserver
Wed, 22 Mar 2023
Stocks to Watch: Coinbase, Agile Therapeutics, Steelcase, SQZ Biotechnologies - MarketWatch
Wed, 22 Mar 2023
SQZ Biotechnologies Stock Jumps 40% On Confirmed Complete ... - Nasdaq
Wed, 22 Mar 2023
SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates - Yahoo Finance
Wed, 22 Mar 2023
SQZ BIOTECHNOLOGIES CO Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K) - Marketscreener.com
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
29 (M) |
| Shares Float |
21 (M) |
|
% Held by Insiders
|
3.1 (%) |
|
% Held by Institutions
|
66.7 (%) |
|
Shares Short
|
255 (K) |
|
Shares Short P.Month
|
264 (K) |
Stock Financials |
|
EPS
|
-2.72 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.33 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-358.7 |
|
Return on Assets (ttm)
|
-24.6 |
|
Return on Equity (ttm)
|
-77.1 |
|
Qtrly Rev. Growth
|
-27.4 |
|
Gross Profit (p.s.)
|
-1.47 |
|
Sales Per Share
|
0.74 |
|
EBITDA (p.s.)
|
-2.63 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-84 (M) |
|
Levered Free Cash Flow
|
-46 (M) |
Stock Valuations |
|
PE Ratio
|
-0.23 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0.25 |
|
Price to Sales
|
0.81 |
|
Price to Cash Flow
|
-0.22 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
